DARA BioSciences Product Gelclair(R) Attains Market

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DARA BioSciences Product Gelclair(R) Attains Market Leadership Position in U.S. Retail Market

RALEIGH, NC --(Marketwired - October 14, 2014) - DARA BioSciences, Inc . ( NASDAQ : DARA ), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today that its product, Gelclair ® , indicated for the management of oral mucositis, has attained a major milestone in the U.S. market by becoming the number one oral gel barrier prescription product in the retail sector.

Based on Symphony Health Solutions data, Gelclair has had more prescriptions filled in the retail sector than any other prescription oral gel barrier agent. Starting in June of this year, Gelclair became the most frequently prescribed retail oral gel barrier agent and continues to be the leader in this class as reported through August 2014. The latest data (through August 2014) indicates that Gelclair is the only product in the oral gel barrier class to show continued month over month retail prescription growth since February of this year.

Christopher G. Clement, DARA CEO and President, stated, "The increase in retail Gelclair prescriptions demonstrates a strong brand image and product awareness among prescribers and patients. This allows our team to achieve continued expansion of Gelclair into the artificial saliva and magic mouthwash markets, which each contain products with broad use but limited scientific documentation in treating oral mucositis. Furthermore, this milestone and the success of Gelclair affirm our belief in the commercial strategy of establishing DARA as a leader in oncology supportive care, as well as our confidence in continued positive sales momentum."

Clement continued, "Gelclair has also recently been approved for preferred formulary position by both national payers and leading cancer institutions, giving millions of people access to the product. These recent placements combined with DARA's 'No Coupon, No Co-Pay, No Hassles' program have made Gelclair the number one choice in gel barriers in the retail segment among prescribing health care providers. We anticipate additional formulary approvals as interest in the product continues to grow."

DARA CMO and Chairman of the Board, David J. Drutz, M.D., added, "We are particularly excited about the recent publication of a randomized trial by Rasero et al*, which showed significant oral mucositis pain control benefit in patients undergoing hematopoietic stem-cell transplantation. Oral mucositis is encountered in 30-90% of this in-hospital patient population, depending on the intensity of pre-transplant induction therapy, and is one of the most distressing and debilitating complications of this procedure. These new data indicate that Gelclair can be of substantial value in managing the painful symptoms of oral mucositis in this group of seriously immunosuppressed patients. Oral mucositis is a common side effect of cancer treatment regimens, with approximately 400,000 patients developing the condition each year. Among the most seriously affected are recipients of bone marrow transplants or patients receiving chemoradiation for head and neck cancer. These and other cancer-related patient populations represent important emerging marketing opportunities for Gelclair."

* Rasero L, Marsullo M, Dal Molin A. Assessing the effectiveness of Gelclair ® in the prevention and therapy of stomatitis in patients undergoing hematopoietic stem-cell transplantation: a randomized trial. Professioni infermieristiche 2014, 67:15-20 (English abstract available on PubMed (PMID:24762768))

About DARA BioSciences, Inc. DARA BioSciences Inc. of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments.

DARA holds exclusive U.S. marketing rights to both Soltamox® (tamoxifen citrate) oral solution and Gelclair®. DARA licensed the U.S. rights to Soltamox® from UK-based Rosemont Pharmaceuticals, Ltd., and Gelclair® from the Helsinn Group in Switzerland. Under an agreement with Innocutis, DARA also markets Bionect® (hyaluronic acid sodium salt, 0.2%).

Soltamox® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, is indicated for the treatment of metastatic breast cancer, the adjuvant treatment of node-positive breast cancer in postmenopausal women, the reduction in risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS), and for the reduction of the incidence of breast cancer in women at high risk for breast cancer. Currently, there are more than 1.8 million prescriptions of tamoxifen written on an annual basis in the United States. Between 30 and 70 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer recurrence.

Tamoxifen Important Safety Information

Tamoxifen citrate is contraindicated in women who require concomitant coumadin-type anticoagulant therapy, in women with a history of deep vein thrombosis or pulmonary embolus, and in women with known hypersensitivity to the drug or any of its ingredients. Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. The most common adverse reactions to tamoxifen treatment are (incidence > 20%) hot flashes, fluid retention, vaginal discharge, vaginal bleeding, vasodilatation, nausea, irregular menses, weight loss, and musculoskeletal events.

Tamoxifen carries the following Boxed Warning:

WARNING - For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence rates for these events were estimated from the NSABP P-1 trial (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women ). Uterine malignancies consist of both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20 for tamoxifen vs. 0.71 for placebo) and uterine sarcoma (incidence rate per 1,000 women-years of 0.17 for tamoxifen vs. 0.0 for placebo)*. For stroke, the incidence rate per 1,000 women-years was 1.43 for tamoxifen vs. 1.00 for placebo**. For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75 for tamoxifen versus 0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.

*Updated long-term follow-up data (median length of follow-up is 6.9 years) from NSABP P-1 study. See WARNINGS, Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma in Prescribing Information. **See Table 3 under CLINICAL PHARMACOLOGY, Clinical Studies in Prescribing Information.

The full Prescribing Information for Soltamox is available at www.soltamox.com/prescribing-information .

Gelclair® is an alcohol-free bio adherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. Gelclair should not be used by patients with a known or suspected hypersensitivity to the product or any of its ingredients. Under an agreement with Innocutis, DARA also markets Bionect® (hyaluronic acid sodium salt, 0.2%) a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. Bionect should not be used by patients with known hypersensitivity to any of its ingredients. For further information on Gelclair and Bionect and the Full Prescribing Information please visit www.Gelclair.com and www.Bionect.com .

In early 2014, DARA kicked off its new partnership with Alamo Pharma Services, a subsidiary of Mission Pharmacal, in deploying a dedicated 20-person national sales team in the U.S. oncology market. In addition to promoting DARA's products Soltamox, Gelclair and Bionect, this specialized oncology supportive care sales team also provides clinicians with access to three Mission Pharmacal products: Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral® (for chemotherapy/radiation therapy-induced dry mouth).

Important Safety Information and full Prescribing Information for Mission Pharmacal's products may be found at: www.Ferralet.com , www.Binosto.com , and www.Aquoral.com .

DARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and has granted DARA two separate Orphan Drug Designations for the treatment of multiple myeloma and for the treatment of painful, chronic chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics (CCIPN).

For more information please visit our web site at www.darabio.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the implementation our "No Coupon, No Co-pay, No Hassles" program, the intended effects of the program, our ability to increase the availability and distribution of our Gelclair product, the expected effect of the program on demand for our Soltamox and Gelclair products and our ability to increase sales of our Soltamox and Gelclair products, including through the implementation of the "No Coupon, No Co-pay, No Hassles" program. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the "Risk Factors" described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC") and in our other periodic filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT Corporate Contact: Jim Polson FTI Consulting 312-553-6730 Jim.polson@fticonsulting.com Media Contact: David Connolly LaVoie Health Sciences 617-374-8800, Ext. 108 dconnolly@lavoiegroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 115

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 106

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 127

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 119

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 17

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 5

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
SHIFTAIon Puts Governance at Center of AI Migration

Updated Category News Views 69

Legacy code is where grand AI promises usually go to get mugged by reality. ACL Digital’s new SHIFTAIon platform is taking a sensible swing at that ugly problem: not merely generating code faster, but putting discovery, architecture decisions, testing, security checks, reviewer signoffs, and reporting into one controlled modernization process. That distinction matters....

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 26

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 12

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Share Buybacks and Voting Rights Dynamics

Updated Category News Views 130

Overview of Share Buybacks In recent financial news, Octopus AIM VCT plc has engaged in a strategic move by purchasing its own shares. This action is often a signal of confidence in the company's future and an investment in its own value. Details of the Transaction The company has recently announced the acquisition of 590,908 ordinary shares at a price of 47.27p each....

Continue Reading
Kojamo's Financial Report Highlights: Growth and Outlook

Updated Category News Views 186

Overview of Kojamo plc's Financial Performance Kojamo plc has recently published its financial report, highlighting significant changes and developments in their occupancy rates and revenues for the first half of the fiscal year. This report is particularly important for investors and stakeholders keen on understanding the company's financial health. Financial Highlights...

Continue Reading
Silicom Ltd. Partners with U.S. Firm for Edge Networking Growth

Updated Category News Views 167

Silicom Ltd. Partners with Provider for Edge Networking Solutions - $1 million annual run rate with potential for a significant multi-million-dollar scale-up - Silicom Ltd. (NASDAQ: SILC), a recognized leader in networking and data infrastructure solutions, has announced an exciting collaboration with a U.S.-based provider specializing in Edge networking solutions...

Continue Reading
Understanding the Ongoing Securities Case Against Five Below, Inc.

Updated Category News Views 120

Overview of the Class Action Lawsuit Against Five Below, Inc. As an investor, it's essential to stay informed about your rights, especially with ongoing legal matters. Currently, a notable class action lawsuit is underway involving Five Below, Inc. (NASDAQ: FIVE), which is particularly relevant for its shareholders. Class Period Details The allegations pertain to the time...

Continue Reading
Worthington Enterprises to Boost Portfolio with LSI Group Buyout

Updated Category News Views 169

Worthington Enterprises Expands Its Portfolio with Major Acquisition Worthington Enterprises Inc. (NYSE: WOR), renowned for its innovative designs and manufacturing prowess, has officially announced its intent to acquire LSI Group, LLC. This major acquisition positions Worthington Enterprises to enhance its offerings and market presence in the metal roofing sector....

Continue Reading